A panel of experts discuss renal cell carcinoma (RCC) using evidence-based data presented at the ASCO GU 2022 Annual Meeting this year.
Sifting Through Data in Lung Cancer and Leukemia: Drs Levy and Saint Fleur
Updated MANIFEST-2 Data With Pelabresib/Ruxolitinib Support Paradigm Shift in Myelofibrosis
Ponatinib Showcases Long-Term Efficacy, Safety in CP-CML With T315I Mutations
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC